Distúrbio clonal de células-tronco hematopoéticas, caracterizado pela proliferação na medula óssea de uma ou mais linhagens mieloides (isto é, granulocíticas, eritróides, megacariocíticas e mastócitos). É principalmente uma neoplasia de adultos. (OMS 2008)
Introdução
O que você precisa saber de cara
Síndrome mieloproliferativa 8p11 é um câncer de sangue que envolve diferentes tipos de células sanguíneas. As células sanguíneas são divididas em vários grupos (linhagens) com base no tipo de célula precoce da qual descendem. Duas dessas linhagens são as células mieloides e as células linfoides. Pessoas com síndrome mieloproliferativa 8p11 podem desenvolver tanto câncer de células mieloides quanto câncer de células linfoides.
A condição pode ocorrer em qualquer idade. Geralmente começa como um distúrbio mieloproliferativo, que se caracteriza por um número elevado de glóbulos brancos (leucócitos). A maioria das pessoas afetadas também apresenta um excesso de células mieloides conhecidas como eosinófilos (eosinofilia).
Além de um distúrbio mieloproliferativo, muitas pessoas com síndrome mieloproliferativa 8p11 desenvolvem linfoma, que é uma forma de câncer de sangue que envolve células linfoides. As células linfoides cancerosas crescem e se dividem nos linfonodos, formando um tumor que aumenta os linfonodos. Na maioria dos casos de síndrome mieloproliferativa 8p11, as células cancerosas são células linfoides chamadas células T. O linfoma pode se desenvolver ao mesmo tempo que o distúrbio mieloproliferativo ou mais tarde.
Na maioria das pessoas com síndrome mieloproliferativa 8p11, o distúrbio mieloproliferativo evolui para um câncer de sangue de crescimento rápido chamado leucemia mieloide aguda.
A produção rápida de células mieloides e linfoides causada por esses cânceres resulta em aumento do baço e do fígado (esplenomegalia e hepatomegalia, respectivamente). A maioria das pessoas com síndrome mieloproliferativa 8p11 apresenta sintomas como fadiga ou sudorese noturna. Algumas pessoas afetadas não apresentam sintomas, e a condição é descoberta por meio de exames de sangue de rotina.
Fonte: MedlinePlus Genetics (NLM/NIH), traduzidoDistúrbio clonal de células-tronco hematopoéticas, caracterizado pela proliferação na medula óssea de uma ou mais linhagens mieloides (isto é, granulocíticas, eritróides, megacariocíticas e mastócitos). É principalmente uma neoplasia de adultos. (OMS 2008)
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 72 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 144 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
51 genes identificados com associação a esta condição.
Pierpont syndrome
An autosomal dominant syndrome characterized by multiple congenital anomalies, global developmental delay, learning disability, palmar and plantar fat pads, and distinctive facial characteristics, especially when smiling.
Growth hormone insensitivity syndrome with immune dysregulation 1, autosomal recessive
An autosomal recessive form of growth hormone insensitivity syndrome, a congenital disease characterized by short stature, growth hormone deficiency in the presence of normal to elevated circulating concentrations of growth hormone, resistance to exogeneous growth hormone therapy, and recurrent infections. Most, but not all, patients have features of immune dysregulation.
Microphthalmia, syndromic, 2
A very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.
Spinocerebellar ataxia 35
A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA35 patients commonly show upper limb involvement and torticollis. There is no cognitive impairment.
Wiedemann-Steiner syndrome
A syndrome characterized by hairy elbows (hypertrichosis cubiti), intellectual disability, a distinctive facial appearance, and short stature. Facial characteristics include long eyelashes, thick or arched eyebrows with a lateral flare, and downslanting and vertically narrow palpebral fissures.
Skeletal defects, genital hypoplasia, and impaired intellectual development
A disorder characterized by intellectual disability, craniofacial dysmorphism, microcephaly and short stature. Additional features include absence of the thumbs, hypoplasia of the radii and ulnae, additional vertebrae and ribs, retarded bone age and genital hypoplasia.
Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections
A rare disorder of immunity and connective tissue characterized by immunodeficiency, chronic eosinophilia, distinctive coarse facial appearance, abnormal dentition, hyperextensibility of the joints, and bone fractures.
Bone marrow failure syndrome 2
An autosomal recessive disorder characterized by trilineage bone marrow failure, bone marrow hypocellularity, learning difficulties, and microcephaly. Insufficient hematopoiesis results in peripheral blood cytopenias, affecting myeloid, erythroid and megakaryocyte lines. Cutaneous features and increased chromosome breakage are not features.
Carney complex 1
CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas.
Leukemia, chronic myeloid
A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.
Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia
A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia.
Tatton-Brown-Rahman syndrome
An overgrowth syndrome characterized by a distinctive facial appearance, tall stature and intellectual disability. Facial gestalt is characterized by a round face, heavy horizontal eyebrows and narrow palpebral fissures. Less common features include atrial septal defects, seizures, umbilical hernia, and scoliosis.
Neurofibromatosis 1
A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.
Piebald trait
Autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes.
Leukemia, chronic myeloid
A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.
Amegakaryocytic thrombocytopenia, congenital, 1
An autosomal recessive form of congenital amegakaryocytic thrombocytopenia, a hematologic disorder characterized by severe reduction of megakaryocytes and platelets at birth, and evolving into generalized bone marrow aplasia during childhood.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
X-linked dyserythropoietic anemia and thrombocytopenia
Disorder characterized by erythrocytes with abnormal size and shape, and paucity of platelets in peripheral blood. The bone marrow contains abundant and abnormally small megakaryocytes.
LEOPARD syndrome 1
A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
Celiac disease 13
A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes.
Leukemia, juvenile myelomonocytic
An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
Medicamentos aprovados (FDA)
1 medicamento encontrado nos registros da FDA americana.
Variantes genéticas (ClinVar)
44 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 24 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
386 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Doença mieloproliferativa crônica
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 37 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
91 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
653 ensaios clínicos encontrados, 157 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 2.377
Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry.
Philadelphia-negative myeloproliferative neoplasms are clonal blood disorders characterized by abnormal blood cell production. This study explores the clinical and epidemiological profiles of 111 Ecuadorian patients diagnosed with Philadelphia-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, between 2014 and 2023. Patients were treated in different institutions, with clinical data collected on disease progression, complications, and survival. Polycythemia vera was the most common subtype (45.9%), followed by essential thrombocythemia (42.3%) and primary myelofibrosis (9%). The JAK2 V617F mutation was most prevalent in essential thrombocythemia (53.2%) and polycythemia vera (41.2%). Hydroxyurea, the most widely used treatment, was prescribed to 77% of the patients. Disease progression to myelofibrosis occurred in three polycythemia vera and two essential thrombocythemia cases, meanwhile One case of primary myelofibrosis and one case of myeloproliferative neoplasm, unclassified, progressed to acute myeloid leukemia. Survival rates varied across the cohort; notably, certain patients with polycythemia vera and essential thrombocythemia achieved survival durations of up to 19 years. These results reveal a relatively homogeneous epidemiological profile across the Latin American region and underscore the need for more multicenter studies to better characterize pH- MPNs in Ecuador and the region, to optimize diagnostic and treatment strategies.
Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm.
Patients with myeloproliferative neoplasms (MPN) are known to complicate pulmonary hypertension (PH). Half of patients with MPN-associated PH have chronic thromboembolic PH (CTEPH); however, the prevalence, clinical characteristics, and treatment response remain unclear. Nagoya PH registry database was retrospectively analyzed. Of 129 CTEPH patients, 82 were included. Clinical characteristics and treatment response were compared between CTEPH patients with MPN (MPN group) and those without MPN (non-MPN group). As the treatment course at Nagoya University Hospital, medical treatment was initiated before performing balloon pulmonary angioplasty (BPA)/pulmonary endarterectomy (PEA). Right heart catheterization was performed at pre-medication, post-medication, and post-BPA/PEA. Seven patients had concomitant MPN as the underlying cause for CTEPH, accounting for 5.4% (7/129) of CTEPH cases. Baseline clinical characteristics were comparable between the MPN and non-MPN groups. No significant difference was observed in ∆pulmonary vascular resistance (PVR) from baseline to post-medical treatment (-3.59 WU in the MPN group vs. -3.80 WU in the non-MPN group; P=0.67) and baseline to post-BPA/PEA (-6.92 WU in the MPN group vs. -7.60 WU in the non-MPN group; P=0.35). As hemodynamic responses to treatment in CTEPH patients with MPN were comparable with those without MPN, their prognosis may improve with multimodal CTEPH treatment similar to non-MPN cases.
Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.
QuANTUM-First is a randomised phase 3 trial in individuals with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD) positive, showing a survival advantage for quizartinib versus placebo plus standard induction and consolidation chemotherapy with or without transplantation, followed by single-agent maintenance therapy. We evaluated the impact of quizartinib on patient-reported outcomes and health-related quality of life using the European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire. In this global, multicentre, randomised, placebo-controlled, phase 3 trial, we recruited adults aged 18-75 years, with FLT3-ITD-positive newly diagnosed AML or AML secondary to myelodysplastic syndrome or myeloproliferative neoplasm, and with an Eastern Cooperative Oncology Group performance status of 0-2. Participants were randomly allocated (1:1) to quizartinib (40 mg/day) or placebo plus standard 7 + 3 induction chemotherapy, and then received standard consolidation chemotherapy with high-dose cytarabine plus quizartinib (40 mg/day) or placebo, allogeneic haematopoietic cell transplantation (allo-HCT), or both, followed by maintenance with single-agent quizartinib (30-60 mg/day) or placebo for up to 36 cycles. Randomisation was managed via an interactive web and voice response system. Patient-reported outcome endpoints, assessed using the European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire, were exploratory and analyses were based on the patient-reported outcome intention-to-treat analysis set. Treatment effects on patient-reported outcomes were assessed using the mixed-effects model for repeated measures, time to sustained improvement, and time until definitive deterioration analyses. A minimal clinically important difference score of 10 or higher for each subscale was defined as clinically meaningful. This trial is registered with ClinicalTrials.gov, NCT02668653, and is completed. Participants were enrolled between Sept 27, 2016, and Aug 14, 2019. Of 539 randomly allocated participants, 509 (278 [55%] female and 231 [45%] male) were included in the patient-reported outcome analysis set, 254 in the quizartinib group and 255 in the placebo group. The overall median follow-up was 39·2 months (IQR 31·9-45·8). Baseline patient-reported outcome scores were similar between groups. The change in global health status and quality of life score (GHS-QoL) from baseline was above the minimal clinically important difference from consolidation onwards in both groups. The treatment difference (quizartinib minus placebo) in change from baseline for GHS-QoL (by mixed-effects model for repeated measures) was -2·0 (95% CI -4·8 to 0·7, nominal p=0·15), indicating no substantial difference between groups, further confirmed by time to sustained improvement (subdistribution hazard ratio [SHR] 1·126 [95% CI 0·904 to 1·403], nominal p=0·28) and time until definitive deterioration (hazard ratio 0·81 [95% CI 0·51 to 1·28], nominal p=0·37) analyses. Longitudinal analyses of the functional and symptom subscales showed no substantially different patterns between groups. For the functional subscales, the SHR ranged from 0·940 to 1·148 (0·737-1·544, nominal p=0·36-0·90). For the symptom subscales, the SHR ranged from 0·965 to 1·407 (0·720-1·989, nominal p=0·28-0·99). The results indicate that quizartinib plus standard chemotherapy prolongs overall survival without adversely affecting patient-reported outcomes and health-related quality of life, with no substantial differences between groups. Future research in real-world settings is warranted to assess the generalisability of these patient-reported outcome results. Daiichi Sankyo.
The function and molecular mechanism of HIF-1α interacted with p-STAT3 in promoting G6PD overexpression in chronic myelogenous leukemia cells.
Chronic myeloid leukemia (CML) is a malignant myeloproliferative neoplasm originating from hematopoietic stem cells, which substantially contributes to the morbidity and mortality among leukemia patients. Our findings demonstrated that glucose-6-phosphate dehydrogenase (G6PD) is aberrantly overexpressed in CML, where it promotes the proliferation of CML cells and modulates their cell cycle distribution. Furthermore, we observed a positive correlation between G6PD overexpression and the resistance of CML cells to imatinib. Subsequent mechanistic investigations revealed that the complex formed by the interaction of phosphorylated STAT3 (p-STAT3) and hypoxia-inducible factor 1α (HIF-1α) functions as a novel transcriptional regulator of G6PD, thereby driving its increased expression. Collectively, this study provides compelling evidence that strategies directly targeting p-STAT3/HIF-1α-G6PD may represent an effective therapeutic approach to suppress CML cells proliferation and overcome drug resistance, offering new insights into the diagnosis and clinical management of CML patients.
Impact of Angiotensin-Converting Enzyme Inhibitors on Disease Symptoms in Patients with Chronic Myeloproliferative Neoplasms.
Patients with chronic myeloproliferative neoplasms (MPNs) have upregulated renin-angiotensin-aldosteron system in the bone marrow and suffer from debilitating inflammation-linked symptoms. The use of angiotensin-converting enzyme inhibitors (ACEi) has been shown to improve hematocrit control and thrombotic risk in MPNs. Here, we investigated whether ACEi use may also have an impact on disease-related symptoms in MPNs. This cross-sectional two-center study included 100 consecutive MPN patients who fulfilled the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) at the time of study entry. The use of ACEi correlated with older age, presence of JAK2 mutation, prior thrombosis and different cardiovascular risk factors. Patients using ACEi also presented with higher total symptom score (p = 0.002), more abdominal discomfort (p = 0.031), concentration problems (p = 0.050) and bone pains (p = 0.001). To account for baseline variables that may have potentially impacted MPN symptom control, ACEi users and non-users were case-matched in a 1:1 ratio with respect to sex, age, cytoreductive treatment, and cardiovascular risk factors. Again, there were no differences in almost all MPN-SAF items with respect to ACEi use (p > 0.050 for all analyses). The use of ACEi does not seem to mitigate disease-related symptoms in MPNs. Prospective randomized trials are needed to fully elucidate their therapeutic potential in MPNs.
Publicações recentes
Case Report: The diagnostic and therapeutic crossroads: when myelofibrosis transforms into mixed phenotype acute leukemia.
Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid Leukemia.
Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.
Myeloproliferative neoplasm as a cause of splanchnic vein thrombosis.
Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think?
📚 EuropePMC740 artigos no totalmostrando 199
Improvement of psoriasis with ruxolitinib in a patient with myeloproliferative neoplasm: a therapeutic observation.
Anais brasileiros de dermatologiaFrom Molecular Silence to Lymphoid Blast Phase: Diagnostic and Therapeutic Challenges in a Young Female Patient With Chronic Myeloid Leukemia.
CureusT315I-mutated chronic myeloid leukemia with blast crisis relapse 10 years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy.
Transplant immunologyTherapeutic Plateletpheresis for Thrombocytosis: Critical Analytic Reviews and Original Multicenter Experience.
Transfusion medicine reviews[Mutation characteristics and prognosis of patients with Fanconi anemia signaling pathway gene mutation myeloproliferative neoplasm].
Zhonghua yi xue za zhi[Research Progress of Megakaryocyte Morphology in the Prognosis of Primary Myelofibrosis--Review].
Zhongguo shi yan xue ye xue za zhiClinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry.
Hematology, transfusion and cell therapyCoexistent Antiphospholipid Syndrome with Polycythemia Vera in a 25-year-old Lady Presented with Splenic Vein Thrombosis.
The Journal of the Association of Physicians of IndiaLarge PPM Lead-Associated Thrombus in a JAK2-Positive Patient.
JACC. Case reportsNovel LUC7L::NUTM1 fusion in PDGFRA-rearranged myeloproliferative neoplasm with eosinophilia: a case report.
World journal of surgical oncologyPrevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm.
Circulation reportsPatient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.
The Lancet. HaematologyThe Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.
Current hematologic malignancy reportsRuxolitinib and heart failure outcomes among patients with myelofibrosis.
Leukemia & lymphomaCase Report: Co-existence of BCR::PDGFRA gene fusion and PDGFRA variants in myeloid neoplasm with persistent leukocytosis, large splenomegaly, and eosinophilia.
Frontiers in oncologyConsensus on the use of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a modified Delphi survey.
International journal of hematologySomatic and germline genetic testing pathways in haematological malignancies: Best practice consensus guidelines from the 2025 national meeting organised by UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.
British journal of haematologyEfficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.
Annals of medicineThe function and molecular mechanism of HIF-1α interacted with p-STAT3 in promoting G6PD overexpression in chronic myelogenous leukemia cells.
Cellular signallingGlycolytic-inflammatory crosstalk mediated by Glyco-PMF-Rux hub genes drives PMF progression and ruxolitinib resistance.
Genes & genomicsUse of OCT Imaging in the Treatment of Right Coronary Artery Occlusion Causing NSTEMI as an Initial Complication of Essential Thrombocythaemia.
Case reports in cardiologyThe importance of bone marrow biopsy for chronic myeloid leukemia classification-a case report.
Journal of hematopathologyCD38+ monocytes fuel fibrosis in myeloproliferative neoplasm.
BloodEvacuation of axillary hematoma causing brachial plexus compression in newly diagnosed leukemia: a case report and literature review.
Case reports in plastic surgery & hand surgerySymptom burden and palliative care in patients with hematologic malignancies: a single-center experience.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerImpact of Angiotensin-Converting Enzyme Inhibitors on Disease Symptoms in Patients with Chronic Myeloproliferative Neoplasms.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood TransfusionTranslation and Validation of Myeloproliferative Neoplasm-Symptom Assessment Form (MPN-SAF)-Total Symptom Score (MPN-SAF TSS) Filipino Version.
Acta medica PhilippinaTP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.
American journal of hematologyMechanisms of cerebral venous sinus thrombosis due to essential thrombocythemia: Current status and future perspectives.
Thrombosis researchSarcopenia in Older Adults with Hematologic Malignancies: A Comprehensive Review of Epidemiology, Prognosis, and Interventions.
CancersThe Role and Impact of Non-driver Gene Mutations in Myelofibrosis.
Current hematologic malignancy reportsHeadache and Papilledema Unmasking an Underlying Myeloproliferative Neoplasm: A Case of Chronic Recanalized Cerebral Venous Sinus Thrombosis.
Cureus[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiImaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis.
Cytometry. Part A : the journal of the International Society for Analytical CytologyProgress of investigational bromodomain and extra-terminal domain inhibitors for myelofibrosis therapy.
Expert opinion on investigational drugsLeukocytosis and a JAK2 mutation: The importance of expertise in somatic variant interpretation.
Leukemia research reportsClinical perception and novel insights of chronic myelomonocytic leukemia: a 10-year multi-center retrospective study.
Frontiers in medicineHematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation.
Case reports in hematologyMyeloid sarcoma transformed from myeloproliferative neoplasm: A case report and review of literature.
World journal of clinical oncologyTargeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report.
International journal of molecular sciencesAberrant CD25 and Increased CD123 Expression Are Common in Acute Myeloid Leukemia with KMT2A Partial Tandem Duplication and Are Associated with FLT3 Internal Tandem Duplication.
CancersPolycythemia vera and stiff-person syndrome: a case report.
BMC neurologyFive-year population-based study of essential thrombocythemia in Taiwan: Epidemiology, treatment patterns, and sex-based disparities.
Journal of the Formosan Medical Association = Taiwan yi zhiAcute psychosis following initiation of ruxolitinib in post-polycythaemia vera myelofibrosis case report.
Annals of hematologyThe dual crisis of coronary thrombosis and sepsis in JAK2-mutated essential thrombocytosis: A clinical case report.
MedicinePediatric Essential Thrombocythemia: A Case of a JAK2-Mutated Adolescent With Microvascular Symptoms.
CureusNeutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.
Annals of hematologyEvaluating inflammatory markers in distinguishing polycythemia Vera from secondary polycythemia: a prospect for novel diagnostic marker.
Annals of hematologyA Review of the Pathological and Molecular Diagnosis of Primary Myelofibrosis.
Cancers[Diagnostic work-up of erythrocytosis].
La Revue de medecine interne[BCR::ABL-Negative Triple Negative Myeloproliferative Neoplasm --Review].
Zhongguo shi yan xue ye xue za zhi[The Research Progress of Second Cancer Onset in Myeloproliferative Neoplasms --Review].
Zhongguo shi yan xue ye xue za zhiContemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'.
Current opinion in hematologyPredictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia.
Cancer reports (Hoboken, N.J.)Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.
Current opinion in hematologyTofacitinib Use in a Patient With Rheumatoid Arthritis and Polycythemia Vera: A Case Report.
Clinical case reportsDrosophila Abi maintains blood cell homeostasis by promoting clathrin-mediated endocytosis of Notch.
The Journal of cell biologyHealth-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study.
HemaSphereNoninvasive Evaluation of Chorioretinal and Peripapillary Microvascular Alterations in Essential Thrombocythemia.
Retina (Philadelphia, Pa.)Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis.
CancersMetformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial.
Hematological oncologyConcurrent Presentation of Pure Red Cell Aplasia and Myeloproliferative Neoplasm, Unclassifiable With JAK2 and MPL Mutations.
Case reports in hematologyJuvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.
Blood neoplasiaScreening for an underlying myeloproliferative neoplasm in patients with chronic thromboembolic pulmonary hypertension.
Respiratory medicine and researchQuantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression.
Annals of hematologyHemorrhagic Transformation After Ischemic Stroke in a Case of Essential Thrombocythemia with Hyperfibrinolysis on Thromboelastography.
Internal medicine (Tokyo, Japan)Myelodysplastic/Myeloproliferative Neoplasm in a Dog: A Case Report.
Veterinary medicine and scienceLoss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms.
Experimental hematologyMicroenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.
BloodRisk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.
JCO oncology practiceA Massive Haemothorax Due to Pleural Extramedullary Haematopoiesis in a Patient With Myelodysplastic Syndrome/Myeloproliferative Neoplasm.
CureusRuxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms.
EJHaemCurrent treatments, practical management, and emerging investigational therapies for myelofibrosis.
Expert review of hematologyAtypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options.
HemaSphereIdentification of a Novel miR-122-5p/CDC25A Axis and Potential Therapeutic Targets for Chronic Myeloid Leukemia.
International journal of molecular sciencesChronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation.
International journal of molecular sciencesIntegrin-dependence of extramedullary erythropoiesis in the spleen of Jak2-V617F positive myeloproliferative neoplasm in mice.
Experimental hematologyMyelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications.
Blood reviewsA Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.
American journal of hematologyEvaluating the feasibility of a network meta-analysis comparing treatment options in polycythemia vera.
Journal of comparative effectiveness researchSynchronous Primary Hyperparathyroidism and Polycythemia Vera: A Case Report and Literature Review.
Clinical case reportsMesenchymal stromal cells secretory pattern contributes to oncoinflammatory bone marrow microenvironment in polycythemia vera.
Hematology, transfusion and cell therapyDe Novo Myeloid Sarcoma of the Kidney: A Case Report and Literature Review of Clinical Features and Outcomes.
CureusMacrophages in Hematopoiesis and Related Blood Diseases.
Genomics, proteomics & bioinformaticsChronic Inflammation in Primary Myelofibrosis: In-Depth Insights Into Pathogenesis and Promising Anti-Inflammatory Therapeutic Strategies.
Mediators of inflammationClonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.
HaematologicaJAK inhibitor selection in challenging scenarios of myelofibrosis: a review.
HaematologicaSplenic Artery Aneurysm Associated with Myelofibrosis Managed by Coil Embolization.
Internal medicine (Tokyo, Japan)Impaired IL-10 Receptor Signaling Leads to Inflammation Induced Exhaustion in Hematopoietic Stem Cells.
bioRxiv : the preprint server for biologySevere tophaceous gout in the setting of myelofibrosis: A clinical challenge.
Radiology case reportsPrognostic utility of macrophage polarization (CD68/CD163 ratio) in Egyptian JAK2 positive myeloproliferative neoplasm patients: a single center study.
Diagnostic pathologyEfficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.
Annals of hematologyChallenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms.
CancersThe molecular management of classic myeloproliferative neoplasm.
Journal of the Egyptian National Cancer InstituteValidation and interpretation of the Triple A model in Turkish myeloproliferative neoplasm patients with a focus on overall and thrombosis free survival.
Journal of hematopathologyHereditary spherocytosis concomitant with JAK2V617F-positive primary myelofibrosis: a case report.
Frontiers in oncologyRopeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes.
World journal of clinical oncologyLong-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.
EJHaemA Case of Myeloproliferative Neoplasm-Associated Glomerulopathy in a Patient With Myelofibrosis.
Clinical case reportsClinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases-Case-Based Narrative Review.
BiomedicinesYM155 Restores the Effect of Imatinib in Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines.
Current cancer drug targetsProthrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib.
Thrombosis researchThe impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation.
British journal of haematologyClonal Progression and Leukemic Transformation of a TP53 Mutated Post-Polycythaemia Vera Myelofibrosis.
European journal of haematologyDiscrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey.
Acta haematologicaPremature Myocardial Infarction (MI) Complicated by Cardiac Arrest Secondary to Essential Thrombocythaemia (ET).
CureusAcute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion Transformed From JAK2V617F-Mutated Polycythemia Vera: A Case Report.
CureusTRAKJAK: a complete blood count-based prediction of polycythemia vera at initial erythrocytosis workup to reduce financial and ecological costs.
The American journal of medicineCoexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.
American journal of hematologyIntegrated one-pot RPA-CRISPR/Cas13a platform enables ultrasensitive and field-deployable JAK2 V617F detection for myeloproliferative neoplasm diagnosis.
Journal of pharmaceutical and biomedical analysisRisk of Cardiovascular and Cerebrovascular Diseases in Patients with Myeloid Neoplasms: Results from 1.8 Million Inhabitants of Northwest Italy.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyUncommon Evolution From Acute Myeloid Leukaemia to JAK2-Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From TET2/SRSF2-Mutated Haematopoietic Progenitors.
EJHaemMutational Spectrum and Clinical Outcomes of Myelodysplastic/Myeloproliferative Neoplasms: A Single-Institution Study in Korea with Emphasis on U2AF1.
Journal of clinical medicine[Efficacy of ruxolitinib and prognostic factors in patients with myelofibrosis stratified by age].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiMyeloid Neoplasms with Evidence of the Additive/Cumulative Effect of Molecular Genetic Alterations That "Pave the Way" to a Specific Disease Category or Entity: Lessons Learned from Cases Submitted to the 22nd Meeting of the European Association for Haematopathology/Society of Hematopathology Bone Marrow Workshop Organized by the European Bone Marrow Working Group, Dubrovnik 2024.
Pathobiology : journal of immunopathology, molecular and cellular biologyComparison of the clinicopathological features in myeloproliferative or myelodysplastic neoplasms with SF3B1/JAK2, SF3B1/CALR, or SF3B1/MPL co-mutations.
Leukemia & lymphomaEmerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.
Current hematologic malignancy reportsEfficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.
CancerMyeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures.
Blood advancesEpigenetic risk stratification in juvenile myelomonocytic leukemia by targeted methylation analysis of the BMP4 locus.
Clinical epigeneticsImpact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia.
Current hematologic malignancy reportsRole and prognostic value of oncostatin M and its receptor OSMR in acute myeloid leukemia, myeloproliferative neoplasms and non-hematological malignancies.
Frontiers in oncologyMidkine and TNFSF10 as downstream molecules of type I interferon are involved in the treatment of myelofibrosis.
Biochimica et biophysica acta. General subjectsThe Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies.
Blood and lymphatic cancer : targets and therapyHemorrhagic cardiac tamponade complicating myocardial infarction in a hemodialysis patient with essential thrombocythemia: A case report.
MedicineGenome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40.
BloodGPVI as a Potential New Biomarker for Myelofibrosis Diagnosis.
American journal of hematologyGenetic insights into myeloproliferative neoplasms and unusual sites thrombosis.
Annals of hematologyLow-dose ropeginterferon alfa-2b and peginterferon alfa-2a have comparable efficacy and tolerability in polycythemia vera.
Leukemia researchFloaters as the First Manifestation of Chronic Myeloid Leukemia: A Case Report.
International journal of molecular sciencesUnveiling Cryptic BCR-ABL1 Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies.
International journal of molecular sciencesAquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus.
Dermatology and therapyMetabolomic Profiling Reveals Distinct Signatures in Primary and Secondary Polycythemia.
MetabolitesDifferent Colours of Polycythemia Vera: A Case Series.
CureusThe watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.
BloodZRSR2 loss causes aberrant splicing in JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression.
HemaSphereTYK2 is essential for the therapeutic effect of IFN-α in Jak2V617F-induced murine myeloproliferative neoplasms.
Blood neoplasiaMyeloablative and Reduced Intensity Allogeneic Transplant in Patients with Myeloproliferative Neoplasms.
Hematology/oncology and stem cell therapyCoupling CRISPR scanning with targeted chromatin accessibility profiling using a double-stranded DNA deaminase.
Nature methodsThe Anti-Leukemic Potential of Curcumin in Chronic Myeloid Leukemia: A Systematic Review of In Vitro Studies.
Food science & nutritionCarotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report.
Frontiers in cardiovascular medicineBRAF positive Langerhans cell sarcoma arising from CALR positive myeloproliferative neoplasm: evidence of a clonal progenitor.
Virchows Archiv : an international journal of pathologyCerebral venous sinus thrombosis with head trauma and myeloproliferative neoplasm-unclassifiable: A case report.
MedicineImpact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part Two - The team and patient care experiences.
Canadian oncology nursing journal = Revue canadienne de nursing oncologiqueFat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis.
Tomography (Ann Arbor, Mich.)Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One - From timeliness of triage to cost-saving.
Canadian oncology nursing journal = Revue canadienne de nursing oncologiqueThe Causal Role of the Gut Microbiota-Plasma Metabolome Axis in Myeloproliferative Neoplasm Pathogenesis: A Mendelian Randomization and Mediation Analysis.
MetabolitesPreclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.
Blood advancesPlatelet parameters and their role in myeloproliferative neoplasms, immune-mediated thrombocytopenia, and myelodysplastic syndrome.
Laboratory medicineA Case of Perioperative Management of Tongue Cancer Polycythemia Vera.
Yonago acta medicaExpanding the Spectrum of CSF3R-Mutated Myeloid Neoplasm Beyond Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia: A Comprehensive Analysis of 13 Cases.
Journal of clinical medicineUnmasking systemic mastocytosis: a case of gastrointestinal involvement misdiagnosed as achalasia.
Journal of surgical case reportsLeukocytoclastic Vasculitis in JAK2-Positive Essential Thrombocythemia: A Case of Cytokine-Driven Urticarial Rash Responsive to Ruxolitinib.
European journal of case reports in internal medicineOral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.
The Lancet. HaematologyContemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.
CancerAcquired Haemophilia A Associated With Suspected Chronic Neutrophilic Leukaemia Presenting As Fatal Retroperitoneal Haemorrhage in an Elderly Patient.
CureusCase Report: Myelodysplastic/myeloproliferative neoplasm with concurrent SF3B1, ASXL1, JAK2 and CBL mutations and <15% bone marrow ringed sideroblasts.
Frontiers in oncologyPalisaded Neutrophilic and Granulomatous Dermatitis Associated With ASXL1 -Mutated Chronic Myelomonocytic Leukemia: A Case Report and Literature Review.
The American Journal of dermatopathologyIntersecting paths between autoimmunity and bone marrow fibrosis: the case of autoimmune myelofibrosis.
Autoimmunity reviewsLandscape of somatic mutations in myeloproliferative neoplasm in Pakistani population.
Pakistan journal of medical sciencesReal-world characteristics and treatment patterns in essential thrombocythemia: a population-based cross-sectional study in Taiwan between 2020 and 2021.
Therapeutic advances in hematologyA Rare Case of Myelofibrosis Progressing to BCR-ABL1-Positive Chronic Myeloid Leukemia With Discordant Molecular Testing.
CureusHiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.
BloodRelapse of Acute Myelogenous Leukemia With History of Myeloproliferative Neoplasm and Exacerbation of Pulmonary Hypertension.
JACC. Case reportsZFAS1/STAT3 axis modulates imatinib resistance of chronic myeloid leukemia cells through glucose metabolism reprogramming.
Frontiers in oncologyCD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis.
Journal of cellular and molecular medicineElevated Serum Vitamin B12 Levels and Functional Vitamin B12 Deficiency among Patients with Myeloproliferative Neoplasms.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood TransfusionPrognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study.
Journal of inflammation researchExploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.
Annals of hematologyClinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance.
JCO oncology practiceDefying the Odds: Small Cell Lung Cancer with Essential Thrombocythemia and Secondary Cancers.
CureusNovel insights into the ULK2-FIP200-AMPK-mediated regulation of autophagy and BCR::ABL degradation in chronic myeloid leukemia.
Biochemical and biophysical research communicationsPulmonary Artery Thromboembolism as a Complication of Essential Thrombocythemia.
CureusImpact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.
Acta haematologicaThrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression.
BloodCase Report of Hepatic Sinusoidal Obstruction Syndrome Complicated with Myeloproliferative Neoplasm and Focal Segmental Glomerulosclerosis.
Case reports in gastroenterologyA comprehensive overview of patient journey and management decision pathway for myelofibrosis in India: INLAND survey.
BMC cancerTargeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells.
Discover oncologyBleeding Complications in JAK2-Variant Essential Thrombocythemia: A Revisit in 2025.
EJHaem[Avapritinib for systemic mastocytosis with an associated myelodysplastic/myeloproliferative neoplasm: a case report and literature review].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiIdentification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.
Acta haematologicaBone Marrow Basophil Evaluation in Myeloproliferative Neoplasms Using Flow Cytometry.
International journal of laboratory hematologyContemporary CMML Risk Stratification and Management.
Current hematologic malignancy reportsRare manifestations of pediatric chronic myeloid leukemia: a case report on priapism and a literature Review.
Frontiers in oncologyAutophagosome-lysosome mediated secretion of the thrombopoietin receptor is modulated by distinct driver mutations of myeloproliferative neoplasm.
LeukemiaLatent JAK2 V617F-Positive Myeloproliferative Neoplasm With Normal Blood Counts and Recurrent Splanchnic Vein Thrombosis in a Young Woman.
CureusPathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges.
European journal of haematologyCALR Type 1-Like Mutations Increase Endoplasmic Reticulum Free Ca2+ and Induce ERK1/2 Activation Independent of Thrombopoietin Receptor Activation.
Cell biology internationalComparison of ELTS Score with Sokal, Euro and EUTOS Scores in Risk Stratification of Patients with Chronic Myeloid Leukaemia at a Tertiary Care Hospital in Bangladesh.
Mymensingh medical journal : MMJCalR and MPL Driver Mutations and Their Role in the Diagnosis and Clinical Course of JAK2-Unmutated Chronic Myeloproliferative Neoplasm: Results from a Pilot Single-Center Study.
Medicina (Kaunas, Lithuania)A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence.
Bioengineering (Basel, Switzerland)Intermediate-Dose Cytarabine as Postinduction AML Therapy.
NEJM evidenceBIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis.
Blood neoplasiaAML1-ETO and CCND2 overexpression cooperate to drive acute myeloid leukemia initiation and progression.
Journal of leukocyte biologyA phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis.
Leukemia researchTreatment patterns and blood count control in 10,112 patients with polycythemia vera.
Expert review of hematologyA Rare Case of Chronic Myelomonocytic Leukemia in a Patient With Sarcoidosis: Diagnostic and Immunologic Challenges.
CureusGenomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms.
Translational oncologyChromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.
Nature geneticsAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Doença mieloproliferativa crônica.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Doença mieloproliferativa crônica e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
A doença é provocada pela proliferação clonal de células-tronco hematopoéticas na medula óssea. Alterações em genes como MLLT10, STAT5B e BCOR estão descritas em pesquisas associadas à sua patogênese.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Doença mieloproliferativa crônica. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/doenca-mieloproliferativa-cronica
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Doença mieloproliferativa crônica
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Reposicionamento
- fonte: Drug Repurposing Hub
- Ensaios clínicos
- fonte: ClinicalTrials.gov